LifeMD, Inc. LFMD
Nasdaq · XNAS · stock · Services-Offices & Clinics of Doctors of Medicine
Chart by TradingView
5/9
Piotroski F — financial health
-9.85
Altman Z″ — distress risk · distress
21.6%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $194.1M | $14.4M | $166.3M | $6.4M | $23.2M |
| 2024 | $154.8M | -$21.4M | $133.4M | $12.9M | -$7.6M |
| 2023 | $152.5M | -$20.6M | $133.6M | $8.6M | $4.2M |
| 2022 | $119.0M | -$45.5M | $100.4M | -$23.3M | -$11.9M |
| 2021 | $92.9M | -$60.9M | $74.9M | -$33.3M | $21.7M |
| 2020 | $37.3M | -$58.6M | $28.4M | — | -$4.5M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.85 (distress)
- Working capital / assets 0.146
- Retained earnings / assets -3.247
- EBIT / assets -0.109
- Equity / liabilities 0.49
Source: SEC EDGAR filings · CIK 0000948320 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.